Report post
Investing in drug companies awaiting FDA approval can be lucrative, as seen with Pfizer and Moderna's stock rise post-approval of booster shots. Full FDA approval for Pfizer's vaccine further boosted its stock. VectorVest and Cramer highlight the potential of biotech stocks, suggesting one could be worth over $100 billion upon FDA approval. Investors should research thoroughly before investing in such companies due to the uncertainty and risks involved in the FDA approval process.

The World's Leading Crypto Trading Platform

Get my welcome gifts